Archive for November 2023
Data Presentation at Association for Molecular Pathology 2023 Validates Performance of SeptiCyte® RAPID in Immunocompromised Patients and Patients on Immunosuppressive Therapy
SeptiCyte® RAPID may aid clinicians in determining early antibiotic administration and in bundle compliance for immunocompromised patients with intermediate-high and high probabilities of sepsis SEATTLE and BRISBANE, Australia, Nov. 17, 2023 /PRNewswire/ — Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today announced a poster presentation validating the utility of SeptiCyte® RAPID…
Read More“Improving Outcomes For Patients With Sepsis” — Interview from Progress, Potential & Possibilities
“Today we have the honor of being joined by Dr Roland Carlson, who is the Chief Executive Officer of Immuneexpress which is a Seattle-based molecular diagnostic company they’re committed to improving the outcomes for patients suspected of having sepsis and their FDA-cleared SeptiCyte technology is focused on rapidly quantifying from whole blood specific molecular markers…
Read More